The Dermatology Digest

JULY 1, 2024

PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis.

Portfolios 74

Portfolios Safety Clinic Injections 74

New Age Spa Institute

JULY 6, 2023

Las Vegas, known as the entertainment capital of the world, welcomed beauty professionals and skin care enthusiasts from across the globe for the highly anticipated International Esthetics Cosmetics Skincare Conference (IECSC) 2023. body treatments. Let’s dive into the captivating highlights of this exceptional conference.

Esthetics 52

Esthetics Skincare Esthetician Medical Esthetics 52

The Dermatology Digest

MARCH 5, 2024

Food and Drug Administration (FDA) has given its nod to Letybo (foletibotulinumtoxinA) for the treatment of moderate-to-severe glabellar lines in adults. Hugel resubmitted its application in October 2022 and was denied approval again in 2023. Now, there are six neuromodulators approved for cosmetic use in the U.S.: and Europe.

Branding 74

Branding Injections Safety Facials 74

Aesthetics Advisor

NOVEMBER 7, 2023

Mouthwash is part of the FLCCC I-PREVENT Protocol Best Mouthwashes for COVID-19 according to evidence for 2023 There are lots of great mouthwashes out there, and this list is by no means complete. Instruction: twice a day or after having been out for prevention, and three times a day for early treatment of COVID-19. Review rating 4.7

Ingredients 69

Ingredients Irritation Sanitation Medical 69

Aesthetics Advisor

SEPTEMBER 15, 2023

During this time, the FDA has authorized many treatments that help combat COVID-19. 3 in this COVID-19 early treatment mortality drug league table below. Canadian biotech SaNOtize’s nitric oxide nasal spray Enovid became available in pharmacies in Israel in July 2021 as a treatment for Covid-19. Povidone-iodine is ranked no.

Hospital 69

Hospital Clinic Marketing Medical 69

The Dermatology Digest

APRIL 4, 2024

Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for bimekizumab-bkzx (Bimzelx, UCB), an interleukin(IL)-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). at UCB in a news release. Bimzelx was approved in the U.S. In the U.S.,

Safety 57

Safety Injections Clinic Therapy 57

The Dermatology Digest

SEPTEMBER 30, 2024

Otulfi is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. In February 2023, Fresenius Kabi and Formycon entered into a global commercialization partnership for the ustekinumab biosimilar candidate covering key global markets. and worldwide.

Portfolios 36

Portfolios Partnerships Marketing Safety 36

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). in seborrheic dermatitis.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

APRIL 30, 2024

Eli Lilly has resubmitted its Biologics License Application (BLA) for Lebrikizumab for the treatment of moderate to severe atopic dermatitis (AD), with regulatory action anticipated in the second half of 2024. Lebrikizumab Timeline October 2023 The U.S. There were no concerns with lebrikizumab’s clinical data package, safety, or label.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

MAY 16, 2024

Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, adds: “With only two FDA approved biologics, there is still an urgent need for new treatment options that treat all patient types and lesions, with the opportunity for inflammatory remission. HiSCR75 and beyond).

Safety 68

Safety Clinic Dermatology Office 68

The Dermatology Digest

FEBRUARY 8, 2024

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. The BIG story is Janus kinase ( JAK ) inhibitors,” Dr. Martin says.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

JULY 10, 2024

The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate to severe AD, who are candidates for systemic therapy. The letter stated no concerns about the clinical data package, safety, or label for lebrikizumab.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). The FDA has granted nemolizumab Priority Review for prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

Aesthetics Advisor

FEBRUARY 1, 2024

But about 11% of the time, 4 medical conditions are misdiagnosed, according to research published in BMJ Quality & Safety. Diagnostic errors may cause harm to patients by preventing or delaying appropriate treatment, providing unnecessary or harmful treatment, or resulting in psychological or financial repercussions."

Medical 36

Medical Hospital Safety Training 36

The Dermatology Digest

MARCH 22, 2024

1,2 Benzene has become a more recent focus of attention related to safety concerns, with an increase in independent product testing and also updated regulations by the Food and Drug Administration related to benzene. Public safety is the first priority of the AARS. PMID: 38483533; PMCID: PMC10939128. Federal Register, Vol.

Rosacea 64

Rosacea Document Safety Ingredients 64

The Dermatology Digest

MARCH 11, 2024

Food and Drug Administration (FDA) recently accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

MAY 1, 2024

“With this FDA approval, we are now able to offer both high- and low-concentration, citrate-free formulations of Cyltezo, further expanding treatment access for patients living with certain chronic inflammatory diseases,” says Stephen Pagnotta, Executive Director and Biosimilar Commercial Lead at Boehringer Ingelheim, in a news release.

Injections 36

Injections Clinic Safety Branding 36

The Dermatology Digest

APRIL 23, 2024

Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to Abeona’s Biologics License Application (BLA) for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB).

Marketing 36

Marketing Safety Clinic Sustainability 36

The Dermatology Digest

FEBRUARY 7, 2024

For the study, 255 participants were randomized into six treatment groups (placebo [n=43], 25 mg daily [n=43], 25 mg twice-daily [n=41], 50 mg daily [n=43], 100 mg daily [n=43], and 100 mg twice-daily [n=42]). Improvements were also consistent across Patient Reported Outcomes through Week 16. and Janssen Biotech, Inc.

Safety 36

Safety Clinic Office Dermatology 36

The Dermatology Digest

JANUARY 4, 2024

Ustekinumab is approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The clinical results demonstrated that DMB-3115 and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of quality, safety and efficacy.

Pharmaceutical 36

Pharmaceutical Partnerships Clinic Safety 36

Aesthetics Advisor

AUGUST 7, 2023

The 2023 report from the World Obesity Federation estimates that the economic impact of overweight and obesity will surpass $4.3 In April 2023, a spokesperson for Novo Nordisk, maker of semaglutide, said the drugs are now available in pharmacies nationwide. A broad range of drug interventions can help. trillion annually by 2035.

Diet 36

Diet Extractions Medical Sustainability 36

First Derm

JANUARY 16, 2024

Patient Safety and Success : Prioritizing skin cancer screening helps in safeguarding patient health, significantly enhancing the safety and success rates of cosmetic procedures. Early detection and treatment are crucial for improving the chances of a cure.

Surgery 59

Surgery Scarring Safety Treatments 59

The Dermatology Digest

FEBRUARY 26, 2024

Urticaria symptoms clear within minutes after dosing , and neffy could offer patients a novel treatment option to address existing gaps in the efficacy of currently available antihistamines or biologics.” Food and Drug Administration (FDA) opted not to approve neffy for emergency treatments of severe allergic reactions in September 2023.

Pharmaceutical 36

Pharmaceutical Hospital Clinic Safety 36

The Dermatology Digest

DECEMBER 18, 2023

The new AD guidelines also: • Highlight the safety of the topical calcineurin inhibitors with typical usage once or twice daily. Recommend dupilumab for patients 6 months of age or older with moderate-severe AD refractory, intolerant, or unable to use mid-potency topical treatment, or tralokinumab for similar patients ages 12 years and older.

Dermatitis 36

Dermatitis Partnerships Therapy Diet 36

The Dermatology Digest

JANUARY 10, 2024

Positive clinical data from the Phase 1b trial were announced in October 2023. The trial was a 16-week open-label study assessing the safety, tolerability, pharmacokinetics, and exploratory efficacy of once-daily topical VYN201 in 29 patients with a clinical diagnosis of active nonsegmental vitiligo, in three dose cohorts (0.5%, 1.0%

Clinic 36

Clinic Safety Dermatology Treatments 36

First Derm

DECEMBER 26, 2023

Consult Healthcare Providers When Necessary : Seek professional advice for persistent, severe, or unusual scalp symptoms to ensure accurate diagnosis and effective treatment. 3] Treatment – Dandruff Shampoos: Key Ingredients : Ketoconazole, selenium sulfide, pyrithione zinc, coal tar, salicylic acid.

Management 64

Management Dermatitis Eczema Consultation 64

Aesthetics Advisor

JANUARY 6, 2024

In November 2023, researchers from Cardiff University in the United Kingdom published a comprehensive review in the British Journal of Cancer (BJC) outlining aspirin’s potential to reduce cancer mortality, prevent metastatic cancer spread, and minimize vascular complications.

Vitamin C 36

Vitamin C Safety Therapy Networking 36

Aesthetics Advisor

DECEMBER 3, 2023

Research also suggests krill oil alleviates oxidative stress and iron accumulation, such that it could be used as a treatment for toxicity caused by iron overload. 2023 Jan; 16(1): 130., It's more bioavailable because the EPA and DHA are bound in a phospholipid form, allowing you to take lower doses while still reaping similar results.

Vitamin C 36

Vitamin C Retinol Collagen Diet 36

Aesthetics Advisor

AUGUST 6, 2023

The diet is currently being explored as an additional treatment for cancer, because it may help slow tumor growth. ( More research is being done to determine the safety of the keto diet in the long term. 4 Trusted Source , 30 Trusted Source , 31 Trusted Source ). Alzheimer’s disease.

Diet 36

Diet Medical Management Sustainability 36

The Dermatology Digest

AUGUST 30, 2023

We looked at 20 units in the glabella versus 40, 60, and 80 units,” said Ted Lain, MD, MBA, who presented “Dose-Duration Relationship with Neurotoxins” at Music City SCALE 2023. In other words, how long it takes for patients to maintain no or mild wrinkles in the treatment area, he said. J Drugs Dermatol. 2020 Oct 1;19(10):985-991.

Wrinkles 36

Wrinkles Office Safety Clinic 36

Aesthetics Advisor

AUGUST 6, 2023

It’s just one of many potential uses for the increasingly popular treatment. The 'crapsules,' which have none of the taste or smell as the name suggests, may offer new hope for patients with cirrhosis who are out of treatment options," said Debbie Shawcross, the study’s chief investigator. Can Freeze-Dried Poop Help Liver Disease?

Clinic 36

Clinic Treatments Scarring Office 36

The Dermatology Digest

APRIL 23, 2024

dysphagia after injection to the neck) following low-dose cosmetic or therapeutic injections using FDA-approved products will not require treatment with botulism antitoxin. Symptom onset dates ranged from November 4, 2023, to March 31, 2024. Do not wait for laboratory confirmation to begin treatment.

Injections 36

Injections Hospital Clinic Consultation 36

The Dermatology Digest

OCTOBER 5, 2023

“It all boils down to stress,” said Keira Barr, MD, who presented “Beauty & The Beast: Stress, Trauma, Skin Disease & A Somatic Approach to Healing,” during the “Mind Body Therapies as Treatment Strategy in Dermatology: What is the Evidence?” ” session at the 2023 AAD Innovation Academy in Tampa, Florida. “I

Safety 36

Safety Social Media Therapy Sun Protection 36

Aesthetics Advisor

JANUARY 18, 2024

1 Since then, Korean and Chinese researchers have compiled extensive in vitro, animal, and clinical data on the safety and potential applications of lumbrokinase over the past 30 years. As of April 2023, a simple PubMed keyword search of " lumbrokinase " generated 87 results, with papers dating as far back as 1991.

Pharmaceutical 36

Pharmaceutical Extractions Clinic Safety 36

West Lake Dermatology

NOVEMBER 1, 2023

Updated on November 2, 2023 Undesirable arm contour can be a source of self-doubt, to the point where it affects our quality of life. There are treatments to minimize the appearance of scars that result from either procedure. Originally published on July 5, 2017.

Surgery 69

Surgery Scarring Consultation Consultations 69

Aesthetic Advancements Institute (AAI)

JUNE 20, 2023

Juvéderm’s® newest filler, Volux , has been approved by the FDA and is set to hit medical offices in early 2023. Patients with a history of multiple severe allergies or prone to allergic reactions to lidocaine or the gram-positive bacterial proteins that are found in this filler should be advised to avoid this treatment.

Training 36

Training Injections Medical Facials 36

Aesthetics Advisor

FEBRUARY 28, 2024

In other words, as effective as vitamin C is in prevention and treatment, you can’t make money prescribing or manufacturing it. Vitamin C has always been vital to immune function, but research data also show that it plays an important role in the treatment of several health conditions, including cancer.

Vitamin C 36

Vitamin C Pharmaceutical Hospital Therapy 36